Logo image of OXUR.BR

OXURION NV (OXUR.BR) Stock Fundamental Analysis

EBR:OXUR - Euronext Brussels - BE0974487192 - Common Stock - Currency: EUR

0.056  +0 (+1.82%)

Fundamental Rating

1

Overall OXUR gets a fundamental rating of 1 out of 10. We evaluated OXUR against 73 industry peers in the Biotechnology industry. OXUR may be in some trouble as it scores bad on both profitability and health. OXUR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

OXUR had negative earnings in the past year.
In the past year OXUR has reported a negative cash flow from operations.
In the past 5 years OXUR reported 4 times negative net income.
In the past 5 years OXUR always reported negative operating cash flow.
OXUR.BR Yearly Net Income VS EBIT VS OCF VS FCFOXUR.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

OXUR's Return On Assets of 2.09% is fine compared to the rest of the industry. OXUR outperforms 73.97% of its industry peers.
Industry RankSector Rank
ROA 2.09%
ROE N/A
ROIC N/A
ROA(3y)-183.9%
ROA(5y)-157.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OXUR.BR Yearly ROA, ROE, ROICOXUR.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

With an excellent Profit Margin value of 3966.67%, OXUR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
OXUR has a Operating Margin of 12733.33%. This is amongst the best in the industry. OXUR outperforms 100.00% of its industry peers.
Industry RankSector Rank
OM 12733.33%
PM (TTM) 3966.67%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OXUR.BR Yearly Profit, Operating, Gross MarginsOXUR.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K 10K

More info and screens

0

2. Health

2.1 Basic Checks

OXUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OXUR has more shares outstanding
OXUR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OXUR is higher compared to a year ago.
OXUR.BR Yearly Shares OutstandingOXUR.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
OXUR.BR Yearly Total Debt VS Total AssetsOXUR.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -23.74, we must say that OXUR is in the distress zone and has some risk of bankruptcy.
OXUR's Altman-Z score of -23.74 is on the low side compared to the rest of the industry. OXUR is outperformed by 83.56% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.74
ROIC/WACCN/A
WACC1.67%
OXUR.BR Yearly LT Debt VS Equity VS FCFOXUR.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.22 indicates that OXUR may have some problems paying its short term obligations.
OXUR's Current ratio of 0.22 is on the low side compared to the rest of the industry. OXUR is outperformed by 89.04% of its industry peers.
A Quick Ratio of 0.22 indicates that OXUR may have some problems paying its short term obligations.
OXUR has a worse Quick ratio (0.22) than 89.04% of its industry peers.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.22
OXUR.BR Yearly Current Assets VS Current LiabilitesOXUR.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

OXUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.36%, which is quite impressive.
OXUR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.86%.
OXUR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -76.22% yearly.
EPS 1Y (TTM)99.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.27%
Revenue 1Y (TTM)-98.86%
Revenue growth 3Y-86.15%
Revenue growth 5Y-76.22%
Sales Q2Q%-97.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OXUR.BR Yearly Revenue VS EstimatesOXUR.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
OXUR.BR Yearly EPS VS EstimatesOXUR.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -2K -4K -6K -8K -10K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OXUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OXUR.BR Price Earnings VS Forward Price EarningsOXUR.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, OXUR is valued a bit cheaper than 73.97% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.41
OXUR.BR Per share dataOXUR.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OXUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OXURION NV

EBR:OXUR (5/28/2025, 7:00:00 PM)

0.056

+0 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2024-09-30
Earnings (Next)N/A N/A
Inst Owners0.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap344.96K
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 114.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 21.41
EPS(TTM)-1.48
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS-1.8
TBVpS-1.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.09%
ROE N/A
ROCE -3.5%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 12733.33%
PM (TTM) 3966.67%
GM N/A
FCFM N/A
ROA(3y)-183.9%
ROA(5y)-157.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.02
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 1.87
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.22
Quick Ratio 0.22
Altman-Z -23.74
F-Score4
WACC1.67%
ROIC/WACCN/A
Cap/Depr(3y)1.58%
Cap/Depr(5y)3.23%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.86%
Revenue growth 3Y-86.15%
Revenue growth 5Y-76.22%
Sales Q2Q%-97.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y103.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A